Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 174

  • 3 901 clinical trials
  • 1 548 recruiting
  • 705 conditions
  • 31 countries

Conditions in this area

705 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma165Neoplasm158Acute myeloid leukaemia132Neoplasm malignant128Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+681

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 901 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 901 clinical trials

Hormone-dependent prostate cancer

Not recruiting

Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Prostate cancer metastatic

Not recruiting

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer recurrent+1

Not recruiting

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Gastric cancer

Not recruiting

Study of FOLFIRI with domvanalimab and zimberelimab in patients with advanced gastric or gastro-esophageal junction cancer who progressed after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Ovarian cancer

Not recruiting

Study of Saruparib in Patients with Advanced or Recurrent Ovarian Cancer to Assess Safety and Effectiveness

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Saruparib
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma

Not recruiting

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fondation Franc.Cancerologie Digestive

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:S095035
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Bladder transitional cell carcinoma

Not recruiting

Study of N-803 combined with BCG treatment for patients with early-stage bladder cancer that has not invaded the muscle wall

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Immunitybio Inc.

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Zelenectide Pevedotin in Adults with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer with NECTIN4 Amplification

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zelenectide pevedotin
  • Sponsor:Bicycletx Limited

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab463 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.